We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
RALTEGRAVIR IS A GOOD CHOICE FOR PEOPLE WITH HIV UNDERGOING CANCER CHEMOTHERAPY.
- Authors
Highleyman, Liz
- Abstract
The article reports on the study evaluating the effectiveness of integrase inhibitor raltegravir presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver, Colorado on September 10-13, 2013. It is inferred that raltegravir is highly effective for HIV-positive people receiving cancer chemotherapy. The study was conducted by Harry Torres and colleagues from the University of Texas at Houston M.D. Anderson Cancer Center.
- Subjects
DENVER (Colo.); RALTEGRAVIR; HIV integrase inhibitors; CLINICAL drug trials; CANCER chemotherapy; TORRES, Harry; UNIVERSITY of Texas M.D. Anderson Cancer Center
- Publication
HIV Australia, 2013, Vol 11, Issue 3, p61
- ISSN
1446-0319
- Publication type
Article